BOSTON— The Greater Boston life sciences real estate market is facing its most turbulent period in recent memory, as record-high vacancies, cooling venture capital funding, and mounting macroeconomic pressures reshape the biotech landscape.
According to the latest Q2 2025 report from Colliers, total available lab and life sciences space across the metro now stands at a record 17 million square feet, driven in large part by newly delivered — but entirely vacant — buildings.
With 643,000 SF of new product hitting the market without a single lease in place, direct availability reached 13.4M SF, and when sublease space is factored in, the overall availability rate has surged to 29.7% — an 8.6 percentage point increase from one year ago.
The market has entered a stage where speculative construction has collided headfirst with a demand cliff. The result is a bloated inventory with few immediate takers.
VC Freeze and Economic Uncertainty Stifle Demand
The biotech funding environment is contributing significantly to the slowdown. In the first half of 2025, only $3.3 billion in venture capital flowed into Boston-based biotech firms — the slowest two-quarter stretch since the pandemic-era boom began. Company valuations have plunged, IPO activity has slowed to a crawl (just one this year so far: Sionna Therapeutics), and investor appetite has diminished, driven by poor returns and market volatility.
The S&P Biotech Index is down 50% from its 2021 peak, while broader concerns about Federal policy — including potential cuts to NIH funding and staffing reductions at the FDA — have further chilled sentiment. MassBio, in its Q2 report, raised alarm bells over the long-term implications for the sector.
Tenants, especially early-stage firms, are shrinking their real estate footprints. Where biotech companies once sought up to 8M SF in 2021, today they’re in the market for just 2.8M SF — a nearly two-thirds reduction in active demand.
Boston Proper: Big Supply,…